You are viewing the site in preview mode
Skip to main content
| |
All patients (N = 120)
|
HBeAg-positive (n = 67)
|
HBeAg-negative (n = 53)
|
|---|
|
TDF/TAF (n = 43)
|
ETV (n = 24)
|
p value
|
TDF/TAF (n = 17)
|
ETV (n = 36)
|
p value
|
|---|
|
Age (years)
|
42.9 (34.0–55.0)
|
38.0 (31.0–52.0)
|
43.8 (38.3–56.0)
|
0.136
|
55.0 (41.2–62.1)
|
40.9 (35.8–50.0)
|
0.004
|
|
Number of male patients
|
76 (63.3%)
|
25/43 (58.1%)
|
16/24 (66.7%)
|
0.604
|
11/17 (64.7%)
|
29/36 (80.6%)
|
0.002
|
|
HBcrAg (log U/mL)
|
3.64 (2.24–5.23)
|
5.23 (4.36–5.63)
|
4.87 (3.40–5.34)
|
0.066
|
2.03 (1.35–2.70)
|
2.25 (1.43–2.99)
|
0.517
|
|
Percentage of patients with undetectable HBcrAg*
|
0%
|
0%
|
0%
|
N/A
|
0%
|
0%
|
NA
|
|
ALT
|
73 (53–138)
|
79 (58–144)
|
89 (49–304)
|
0.646
|
57 (46–79)
|
72 (54–153)
|
0.099
|
|
Percentage of patients with elevated ALT
|
103/120 (85.8%)
|
37/43 (86.0%)
|
21/24 (87.5%)
|
1.00
|
16/17 (94.1%)
|
29/36 (80.6%)
|
0.412
|
|
Percentage of patients with cirrhosis
|
7/120 (5.8%)
|
0/43 (0%)
|
0/24 (0%)
|
N/A
|
0/17 (0%)
|
7/36 (19.4%)
|
0.082
|
- Continuous variables were expressed as median (interquartile range)ALT: alanine aminotransferase, ETV: entecavir, HBcrAg: hepatitis B core-related antigen, HBeAg: hepatitis B e antigen, TAF: tenofovir alafenamide, TDF: tenofovir disoproxil fumarate
- *Undetectable serum HBcrAg is defined as < 0.1 log U/mL
